Aripiprazolo (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Aripiprazolo" in Italian language version.

refsWebsite

Global rank Italian rank

25nih.gov

4^th place

9^th place

19doi.org

2^nd place

7^th place

4oadoi.org

799^th place

22^nd place

3archive.org

6^th place

8^th place

2archive.today

14^th place

11^th place

1webmd.com

1,169^th place

2,954^th place

1wiley.com

222^nd place

243^rd place

1worldcat.org

5^th place

26^th place

1unibo.it

4,963^rd place

325^th place

1doai.io

low place

3,405^th place

1aspetjournals.org

6,663^rd place

5,217^th place

1nature.com

234^th place

226^th place

1psychiatryonline.org

4,032^nd place

3,374^th place

1psychiatrist.com

low place

1sagepub.com

731^st place

1,032^nd place

archive.org

Bowles TM, Levin GM, Aripiprazole: a new atypical antipsychotic drug, in The Annals of Pharmacotherapy, vol. 37, n. 5, maggio 2003, pp. 687–94, PMID 12708948.
Brunton Laurence, Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th Edition, McGraw-Hill, 2011, pp. 406–410, ISBN 978-0-07-162442-8.
Carstairs SD, Williams SR, Overdose of aripiprazole, a new type of antipsychotic, in The Journal of Emergency Medicine, vol. 28, n. 3, aprile 2005, pp. 311–3, DOI:10.1016/j.jemermed.2004.09.013, PMID 15769575.

archive.today

Kinghorn WA, McEvoy JP, Aripiprazole: pharmacology, efficacy, safety and tolerability, in Expert Review of Neurotherapeutics, vol. 5, n. 3, maggio 2005, pp. 297–307, DOI:10.1586/14737175.5.3.297, PMID 15938662. URL consultato l'8 dicembre 2020 (archiviato dall'url originale il 31 dicembre 2014).
Zaidi SH, Faruqui RA, Aripiprazole is associated with early onset of Tardive Dyskinesia like presentation in a patient with ABI and psychosis, in Brain Injury, vol. 22, n. 1, gennaio 2008, pp. 99–102, DOI:10.1080/02699050701822493, PMID 18183513. URL consultato l'8 dicembre 2020 (archiviato dall'url originale il 31 dicembre 2014).

aspetjournals.org

jpet.aspetjournals.org

Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR, Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist, in The Journal of Pharmacology and Experimental Therapeutics, vol. 315, n. 3, dicembre 2005, pp. 1278–87, DOI:10.1124/jpet.105.092155, PMID 16135699. URL consultato il 30 dicembre 2014.

doai.io

Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, Mailman RB, Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes, in Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, vol. 20, n. 6, giugno 1999, pp. 612–27, DOI:10.1016/S0893-133X(98)00099-2, PMID 10327430. URL consultato il 30 dicembre 2014.

doi.org

dx.doi.org

(EN) Ravindra B Belgamwar e Hany George G El-Sayeh, Cochrane Database of Systematic Reviews, John Wiley & Sons, Ltd, 10 agosto 2011, DOI:10.1002/14651858.cd006622.pub2, ISSN 1465-1858 (WC · ACNP). URL consultato il 25 novembre 2017.
Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, Mailman RB, Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes, in Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, vol. 20, n. 6, giugno 1999, pp. 612–27, DOI:10.1016/S0893-133X(98)00099-2, PMID 10327430. URL consultato il 30 dicembre 2014.
Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR, Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist, in The Journal of Pharmacology and Experimental Therapeutics, vol. 315, n. 3, dicembre 2005, pp. 1278–87, DOI:10.1124/jpet.105.092155, PMID 16135699. URL consultato il 30 dicembre 2014.
(EN) David A Shapiro, Sean Renock e Elaine Arrington, Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology, in Neuropsychopharmacology, vol. 28, n. 8, 21 maggio 2003, pp. 1400–1411, DOI:10.1038/sj.npp.1300203. URL consultato il 25 novembre 2017.
In This Issue, in American Journal of Psychiatry, vol. 165, n. 8, 1º agosto 2008, pp. A46–A46, DOI:10.1176/appi.ajp.2008.165.8.A46. URL consultato il 25 novembre 2017.
Kegeles LS, Slifstein M, Frankle WG, Xu X, Hackett E, Bae SA, Gonzales R, Kim JH, Alvarez B, Gil R, Laruelle M, Abi-Dargham A, Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride, in Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, vol. 33, n. 13, dicembre 2008, pp. 3111–25, DOI:10.1038/npp.2008.33, PMID 18418366. URL consultato il 30 dicembre 2014.
Yokoi F, Gründer G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF, Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride, in Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, vol. 27, n. 2, agosto 2002, pp. 248–59, DOI:10.1016/S0893-133X(02)00304-4, PMID 12093598. URL consultato il 30 dicembre 2014.
Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R, Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology, in Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, vol. 28, n. 8, agosto 2003, pp. 1400–11, DOI:10.1038/sj.npp.1300203, PMID 12784105. URL consultato il 30 dicembre 2014.
(EN) Nguyen CT, Rosen JA e Bota RG, Aripiprazole partial agonism at 5-HT2C: a comparison of weight gain associated with aripiprazole adjunctive to antidepressants with high versus low serotonergic activities, in The Primary Care Companion for CNS Disorders, vol. 14, n. 5, 2012, DOI:10.4088/PCC.12m01386, PMC 3583771, PMID 23469329. URL consultato il 30 dicembre 2014.
Martyn Wood e Charlie Reavill, Aripiprazole acts as a selective dopamine D2 receptor partial agonist, in Expert Opinion on Investigational Drugs, vol. 16, n. 6, giugno 2007, pp. 771–775, DOI:10.1517/13543784.16.6.771. URL consultato il 25 novembre 2017.
(EN) Starrenburg FC e Bogers JP, How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins, in European Psychiatry : the Journal of the Association of European Psychiatrists, vol. 24, n. 3, aprile 2009, pp. 164–70, DOI:10.1016/j.eurpsy.2009.01.001, PMID 19285836.
(EN) Newman-Tancredi A, Heusler P, Martel JC, Ormière AM, Leduc N e Cussac D, Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells, in The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP), vol. 11, n. 3, maggio 2008, pp. 293–307, DOI:10.1017/S1461145707008061, PMID 17897483.
Mallikaarjun S, Salazar DE, Bramer SL, Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers, in Journal of Clinical Pharmacology, vol. 44, n. 2, febbraio 2004, pp. 179–87, DOI:10.1177/0091270003261901, PMID 14747427. URL consultato il 31 dicembre 2014.
Stip E, Tourjman V, Aripiprazole in schizophrenia and schizoaffective disorder: A review, in Clinical Therapeutics, 32 Suppl 1, 2010, pp. S3–20, DOI:10.1016/j.clinthera.2010.01.021, PMID 20152550.
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM, Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis, in Lancet, vol. 382, n. 9896, settembre 2013, pp. 951–62, DOI:10.1016/S0140-6736(13)60733-3, PMID 23810019.
Kinghorn WA, McEvoy JP, Aripiprazole: pharmacology, efficacy, safety and tolerability, in Expert Review of Neurotherapeutics, vol. 5, n. 3, maggio 2005, pp. 297–307, DOI:10.1586/14737175.5.3.297, PMID 15938662. URL consultato l'8 dicembre 2020 (archiviato dall'url originale il 31 dicembre 2014).
Abbasian C, Power P, A case of aripiprazole and tardive dyskinesia, in Journal of Psychopharmacology (Oxford, England), vol. 23, n. 2, marzo 2009, pp. 214–5, DOI:10.1177/0269881108089591, PMID 18515468. URL consultato il 31 dicembre 2014.
Zaidi SH, Faruqui RA, Aripiprazole is associated with early onset of Tardive Dyskinesia like presentation in a patient with ABI and psychosis, in Brain Injury, vol. 22, n. 1, gennaio 2008, pp. 99–102, DOI:10.1080/02699050701822493, PMID 18183513. URL consultato l'8 dicembre 2020 (archiviato dall'url originale il 31 dicembre 2014).
Carstairs SD, Williams SR, Overdose of aripiprazole, a new type of antipsychotic, in The Journal of Emergency Medicine, vol. 28, n. 3, aprile 2005, pp. 311–3, DOI:10.1016/j.jemermed.2004.09.013, PMID 15769575.

nature.com

(EN) David A Shapiro, Sean Renock e Elaine Arrington, Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology, in Neuropsychopharmacology, vol. 28, n. 8, 21 maggio 2003, pp. 1400–1411, DOI:10.1038/sj.npp.1300203. URL consultato il 25 novembre 2017.

nih.gov

ncbi.nlm.nih.gov

Bowles TM, Levin GM, Aripiprazole: a new atypical antipsychotic drug, in The Annals of Pharmacotherapy, vol. 37, n. 5, maggio 2003, pp. 687–94, PMID 12708948.
Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, Mailman RB, Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes, in Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, vol. 20, n. 6, giugno 1999, pp. 612–27, DOI:10.1016/S0893-133X(98)00099-2, PMID 10327430. URL consultato il 30 dicembre 2014.
Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR, Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist, in The Journal of Pharmacology and Experimental Therapeutics, vol. 315, n. 3, dicembre 2005, pp. 1278–87, DOI:10.1124/jpet.105.092155, PMID 16135699. URL consultato il 30 dicembre 2014.
Kegeles LS, Slifstein M, Frankle WG, Xu X, Hackett E, Bae SA, Gonzales R, Kim JH, Alvarez B, Gil R, Laruelle M, Abi-Dargham A, Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride, in Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, vol. 33, n. 13, dicembre 2008, pp. 3111–25, DOI:10.1038/npp.2008.33, PMID 18418366. URL consultato il 30 dicembre 2014.
Yokoi F, Gründer G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF, Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride, in Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, vol. 27, n. 2, agosto 2002, pp. 248–59, DOI:10.1016/S0893-133X(02)00304-4, PMID 12093598. URL consultato il 30 dicembre 2014.
Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA, The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor, in European Journal of Pharmacology, vol. 441, n. 3, aprile 2002, pp. 137–40, PMID 12063084.
Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R, Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology, in Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, vol. 28, n. 8, agosto 2003, pp. 1400–11, DOI:10.1038/sj.npp.1300203, PMID 12784105. URL consultato il 30 dicembre 2014.
(EN) Nguyen CT, Rosen JA e Bota RG, Aripiprazole partial agonism at 5-HT2C: a comparison of weight gain associated with aripiprazole adjunctive to antidepressants with high versus low serotonergic activities, in The Primary Care Companion for CNS Disorders, vol. 14, n. 5, 2012, DOI:10.4088/PCC.12m01386, PMC 3583771, PMID 23469329. URL consultato il 30 dicembre 2014.
Martyn Wood e Charlie Reavill, Aripiprazole acts as a selective dopamine D2 receptor partial agonist, in Expert Opinion on Investigational Drugs, vol. 16, n. 6, giugno 2007, pp. 771–775, DOI:10.1517/13543784.16.6.771. URL consultato il 25 novembre 2017.
(EN) Starrenburg FC e Bogers JP, How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins, in European Psychiatry : the Journal of the Association of European Psychiatrists, vol. 24, n. 3, aprile 2009, pp. 164–70, DOI:10.1016/j.eurpsy.2009.01.001, PMID 19285836.
(EN) Newman-Tancredi A, Heusler P, Martel JC, Ormière AM, Leduc N e Cussac D, Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells, in The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP), vol. 11, n. 3, maggio 2008, pp. 293–307, DOI:10.1017/S1461145707008061, PMID 17897483.
Davies MA, Sheffler DJ, Roth BL, Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology, in CNS Drug Reviews, vol. 10, n. 4, 2004, pp. 317–36, PMID 15592581.
Mallikaarjun S, Salazar DE, Bramer SL, Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers, in Journal of Clinical Pharmacology, vol. 44, n. 2, febbraio 2004, pp. 179–87, DOI:10.1177/0091270003261901, PMID 14747427. URL consultato il 31 dicembre 2014.
Taylor DM, Aripiprazole: a review of its pharmacology and clinical use, in International Journal of Clinical Practice, vol. 57, n. 1, 2003, pp. 49–54, PMID 12587943.
Swainston Harrison T, Perry CM, Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder, in Drugs, vol. 64, n. 15, 2004, pp. 1715–36, PMID 15257633.
Stip E, Tourjman V, Aripiprazole in schizophrenia and schizoaffective disorder: A review, in Clinical Therapeutics, 32 Suppl 1, 2010, pp. S3–20, DOI:10.1016/j.clinthera.2010.01.021, PMID 20152550.
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM, Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis, in Lancet, vol. 382, n. 9896, settembre 2013, pp. 951–62, DOI:10.1016/S0140-6736(13)60733-3, PMID 23810019.
Kinghorn WA, McEvoy JP, Aripiprazole: pharmacology, efficacy, safety and tolerability, in Expert Review of Neurotherapeutics, vol. 5, n. 3, maggio 2005, pp. 297–307, DOI:10.1586/14737175.5.3.297, PMID 15938662. URL consultato l'8 dicembre 2020 (archiviato dall'url originale il 31 dicembre 2014).
DeLeon A, Patel NC, Crismon ML, Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability, in Clinical Therapeutics, vol. 26, n. 5, maggio 2004, pp. 649–66, PMID 15220010.
Abbasian C, Power P, A case of aripiprazole and tardive dyskinesia, in Journal of Psychopharmacology (Oxford, England), vol. 23, n. 2, marzo 2009, pp. 214–5, DOI:10.1177/0269881108089591, PMID 18515468. URL consultato il 31 dicembre 2014.
Zaidi SH, Faruqui RA, Aripiprazole is associated with early onset of Tardive Dyskinesia like presentation in a patient with ABI and psychosis, in Brain Injury, vol. 22, n. 1, gennaio 2008, pp. 99–102, DOI:10.1080/02699050701822493, PMID 18183513. URL consultato l'8 dicembre 2020 (archiviato dall'url originale il 31 dicembre 2014).
Maytal G, Ostacher M, Stern TA, Aripiprazole-related tardive dyskinesia, in CNS Spectrums, vol. 11, n. 6, giugno 2006, pp. 435–9, PMID 16816781.
Carstairs SD, Williams SR, Overdose of aripiprazole, a new type of antipsychotic, in The Journal of Emergency Medicine, vol. 28, n. 3, aprile 2005, pp. 311–3, DOI:10.1016/j.jemermed.2004.09.013, PMID 15769575.
Lofton AL, Klein-Schwartz W, Atypical experience: a case series of pediatric aripiprazole exposures, in Clinical Toxicology (Philadelphia, Pa.), vol. 43, n. 3, 2005, pp. 151–3, PMID 15902787.
Seifert SA, Schwartz MD, Thomas JD, Aripiprazole (abilify) overdose in a child, in Clinical Toxicology (Philadelphia, Pa.), vol. 43, n. 3, 2005, pp. 193–5, PMID 15902794.

oadoi.org

(EN) Starrenburg FC e Bogers JP, How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins, in European Psychiatry : the Journal of the Association of European Psychiatrists, vol. 24, n. 3, aprile 2009, pp. 164–70, DOI:10.1016/j.eurpsy.2009.01.001, PMID 19285836.
(EN) Newman-Tancredi A, Heusler P, Martel JC, Ormière AM, Leduc N e Cussac D, Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells, in The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP), vol. 11, n. 3, maggio 2008, pp. 293–307, DOI:10.1017/S1461145707008061, PMID 17897483.
Stip E, Tourjman V, Aripiprazole in schizophrenia and schizoaffective disorder: A review, in Clinical Therapeutics, 32 Suppl 1, 2010, pp. S3–20, DOI:10.1016/j.clinthera.2010.01.021, PMID 20152550.
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM, Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis, in Lancet, vol. 382, n. 9896, settembre 2013, pp. 951–62, DOI:10.1016/S0140-6736(13)60733-3, PMID 23810019.

psychiatrist.com

article.psychiatrist.com

(EN) Nguyen CT, Rosen JA e Bota RG, Aripiprazole partial agonism at 5-HT2C: a comparison of weight gain associated with aripiprazole adjunctive to antidepressants with high versus low serotonergic activities, in The Primary Care Companion for CNS Disorders, vol. 14, n. 5, 2012, DOI:10.4088/PCC.12m01386, PMC 3583771, PMID 23469329. URL consultato il 30 dicembre 2014.

psychiatryonline.org

ajp.psychiatryonline.org

In This Issue, in American Journal of Psychiatry, vol. 165, n. 8, 1º agosto 2008, pp. A46–A46, DOI:10.1176/appi.ajp.2008.165.8.A46. URL consultato il 25 novembre 2017.

sagepub.com

jop.sagepub.com

Abbasian C, Power P, A case of aripiprazole and tardive dyskinesia, in Journal of Psychopharmacology (Oxford, England), vol. 23, n. 2, marzo 2009, pp. 214–5, DOI:10.1177/0269881108089591, PMID 18515468. URL consultato il 31 dicembre 2014.

unibo.it

acnpsearch.unibo.it

(EN) Ravindra B Belgamwar e Hany George G El-Sayeh, Cochrane Database of Systematic Reviews, John Wiley & Sons, Ltd, 10 agosto 2011, DOI:10.1002/14651858.cd006622.pub2, ISSN 1465-1858 (WC · ACNP). URL consultato il 25 novembre 2017.

webmd.com

(EN) Abilify Oral : Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD, in WebMD. URL consultato il 25 novembre 2017.

wiley.com

onlinelibrary.wiley.com

(EN) Ravindra B Belgamwar e Hany George G El-Sayeh, Cochrane Database of Systematic Reviews, John Wiley & Sons, Ltd, 10 agosto 2011, DOI:10.1002/14651858.cd006622.pub2, ISSN 1465-1858 (WC · ACNP). URL consultato il 25 novembre 2017.

worldcat.org

(EN) Ravindra B Belgamwar e Hany George G El-Sayeh, Cochrane Database of Systematic Reviews, John Wiley & Sons, Ltd, 10 agosto 2011, DOI:10.1002/14651858.cd006622.pub2, ISSN 1465-1858 (WC · ACNP). URL consultato il 25 novembre 2017.